Joseph Aisner is an Oncology physician affiliated with Rutgers. OpenAlex indexes 416 publications with 14,722 citations (h-index 63); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
195 Little Albany St
New Brunswick, NJ 089011914
Telephone
732-235-2465Registry record last updated 15 Nov 2010.
Clinical trials
- Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Sponsor: Rutgers, The State University of New Jersey
- Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Sponsor: University of Medicine and Dentistry of New Jersey
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
47.8%l-Thyroxine47.8%Levothyroxine Sodium100%Part D≥13 patientsBlood & clotting
18.9%Factor Xa inhibitor18.9%Eliquis100%Part D<11 patientsCancer & immunology
17.8%Kinase inhibitor17.8%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2000–2021 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC
Journal of Thoracic Oncology
2018 - Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
JNCI Journal of the National Cancer Institute
2017 - First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Clinical Cancer Research
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Reynold Panettieri, MD
Rutgers
Brenda Kurnik, MD
Rutgers
Dale Schaar
Rutgers
Petros Levounis, MD, MA
Rutgers
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”